The US FDA has approved a new COVID-19 vaccine, mRNA-1283, for adults aged 65 years and older, as well as individuals aged 12 to 64 years with at least one underlying risk factor. It expresses the N-terminal and receptor-binding domains of the SARS-CoV-2 spike glycoprotein Clinical trial In a clinical trial involving 11,454 individuals, the mRNA-1283 vaccine showed a 9.3% higher relative vaccine efficacy (rVE) in individuals aged 12 years and above, and a 13.5% higher rVE in those aged 65 years and older, compared to the mRNA-1273 vaccine.
Dosage and administration For intramuscular use Administer a single 0.2 mL dose at least three months after the last dose of a COVID-19 vaccine Contraindications Do not administer to individuals: With a history of severe allergic reactions to any component of mRNA-1283 Who had a severe allergic reaction after receiving mRNA-1273 or any previous mRNA…
